Monitor the ASCO poster presentation on May 30 for early signs of safety, tolerability, and anti-tumor activity of OP-3136, which could de-risk the asset and provide a near-term catalyst for re-rating. Absent efficacy signals, sentiment may remain muted despite the event.
Price Chart
Executive Summary
Olema Oncology announced upcoming presentations of initial Phase 1 data for OP-3136 and a trial-in-progress overview of its Phase 3 OPERA-02 study at ASCO 2026. The data readout for OP-3136, a novel KAT6 inhibitor, represents an early clinical milestone for the pipeline beyond its lead candidate palazestrant.
Key Facts
- Olema Oncology will present initial Phase 1 clinical data for OP-3136 at ASCO 2026 on May 30, 2026.
- OP-3136 is a novel oral selective KAT6A/B inhibitor being studied in advanced solid tumors and ER+, HER2− breast cancer.
- The company will also present a trial-in-progress poster for the Phase 3 OPERA-02 study of palazestrant plus ribociclib in ER+, HER2− advanced breast cancer on June 1, 2026.
- OP-3136 received FDA IND clearance in December 2024; enrollment is ongoing in the Phase 1 study.
- Palazestrant has FDA Fast Track designation and is in two ongoing Phase 3 trials (OPERA-01 and OPERA-02).
Financial Impact
No financial impact in near term; data readout may influence valuation based on clinical signal.
Risk Factors
- Early-phase data may show limited clinical activity or safety concerns, leading to negative sentiment.
- Lack of near-term commercial catalysts for OP-3136 given its early development stage.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278398 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 7w ago | 8-K | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.26 (−20.85%) |
Aug 10, 2026 7w ago | Press Release | $10.43 $10.36 | ▼ −0.67% | ▲ +0.39% | $8.26 (−20.85%) |
Aug 9, 2026 7w ago | Institutional Cluster | $11.94 $10.99 | ▲ +8.00% | ▲ +7.08% | $8.26 (+30.86%) |
May 26, 2026 18w ago | 8-K | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.26 (−39.08%) |
May 26, 2026 18w ago | Press Release | $13.55 $11.46 | ▼ −15.42% | ▼ −13.48% | $8.26 (−39.08%) |
May 21, 2026 19w ago | 8-K | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.26 (−39.66%) |
May 21, 2026 19w ago | Press Release | $13.68 $10.19 | ▼ −25.51% | ▼ −24.10% | $8.26 (−39.66%) |
May 12, 2026 20w ago | 8-K | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.26 (−40.91%) |
May 12, 2026 20w ago | Press Release | $13.97 $9.82 | ▼ −29.71% | ▼ −27.98% | $8.26 (−40.91%) |
Apr 29, 2026 22w ago | DEFA14A | $14.41 $13.19 | ▼ −8.47% | ▼ −13.69% | $8.26 (−42.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access